Emergent BioSolutions Inc.
HealthcareNYSE:EBS · New York Stock Exchange
-$0.07 today
Vol 0.40M · Avg 0.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.1%
avg -8.1%
ROIC
5.9%
avg 0.1%
ROA
4.0%
avg -1.4%
Analysis
ROE is currently the strongest return metric at 10.1% versus its period average of -8.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joseph C. Papa Jr. | Chief Executive Officer, President & Director | $2.49M | — | 70 | $493,153.00 | 0.96% |
William Hartzel | Senior Vice President of Manufacturing & Bioservices | $1.39M | — | 48 | $185,558.00 | 0.36% |
Richard S. Lindahl | Executive VP & CFO | $1.10M | — | 62 | $374,083.00 | 0.73% |
Coleen Glessner | Executive Vice President of Quality, Ethics & Compliance | $1.04M | — | 55 | $202,201.00 | 0.39% |
Simon C. Lowry | Chief Medical Officer and Head of Research & Development | $845,170.00 | — | 53 | $177,914.00 | 0.34% |
Paul Williams | Senior Vice President of Products Business | $765,052.00 | — | 59 | $162,098.00 | 0.31% |
Frank Vargo | VP & Treasurer | — | — | — | — | — |
Jessica Perl | Senior Vice President, Corporate Secretary & General Counsel | — | — | 45 | $165,286.00 | 0.32% |
Stephanie Duatschek | Chief Global Strategy & Franchise Development Officer | — | — | — | — | — |
Michelle Pepin | Senior Vice President & Chief Human Resource Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$1.52M
Net Sentiment
$1.52M
Net selling
Most Active
DeGolyer Donald W
4 transactions
1–10 of 15
Analysis
Insiders reported 0 buys worth $0.00 and 15 sells worth $1.52M over the last 12 months. That adds up to net selling of $1.52M. DeGolyer Donald W was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +29.4% | -3.2% (14yr)1 analysts |
| Revenue | N/A | N/A | +20.2% | +5.0% (14yr)1 analysts |
| Net Income | N/A | N/A | +38.8% | -1.5% (14yr)1 analysts |
| EBIT | N/A | N/A | +57.0% | -16.6% (14yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +57.0% over three years. Forward estimates point to Revenue at +5.0% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$654.91M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
SNDL Inc.
NASDAQ:SNDL
$369.44M
SIGA Technologies, Inc.
NASDAQ:SIGA
$309.85M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$301.10M
Who manages EBS?
Emergent BioSolutions Inc. (EBS) lists 10 active executives. The top listed executive is Paul Williams, Senior Vice President of Products Business.
Are EBS insiders buying or selling?
Recent insider activity shows net buying of $10.06M.
Explore More
Continue the stock analysis
Jump to another research area for this company.